Company Overview
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.28.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -55.77% |
| 6 Months: | -21.50% |
| 3 Months: | -46.32% |
| 1 Month: | -30.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.08 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 85.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NIKI Niki BioSolutions, Inc. PHARMA | 6.28 | -2.17 | $3.99M | 0.00% | -12.89% | -17.05% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Sep 2025 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | -558.60K | 589.63K | 825.13K |
| Operating Income | 558.60K | -589.63K | -825.13K |
| EBITDA | 275.92K | -589.63K | -825.13K |
| Interest Expense | - | 26.96K | - |
| Pretax Income | -770.35K | -616.60K | -310.54K |
| Tax Provision | - | - | - |
| Net Income | -919.90K | -614.00K | -307.50K |
| Diluted EPS | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.30M | 431.38K | 0 | 0 |
| Cost of Revenue | - | 1.22M | 420.81K | 0 | 0 |
| Gross Profit | - | 80.06K | 10.57K | 0 | 0 |
| Operating Expenses | - | 17.25M | 10.61M | 3.00M | 1.82M |
| Operating Income | - | -17.17M | -10.60M | -3.00M | -1.82M |
| EBITDA | - | -15.62M | -9.22M | -2.70M | -1.82M |
| Interest Expense | 93.60K | - | - | - | - |
| Pretax Income | - | -11.53M | -4.34M | -4.16M | -1.38M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -9.80M | -2.82M | -4.27M | -1.36M |
| Diluted EPS | -7.15 | -2.75 | -0.62 | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 20.87M | 20.64M | 16.13M | 18.69M |
| Current Assets | - | 7.07M | 2.48M | 959.55K | 3.59M |
| Cash & Equivalents | - | 1.88M | 2.01M | 874.24K | 3.45M |
| Inventory | 35.77K | 27.72K | 0 | - | - |
| Receivables | 78.72K | 174.43K | 47.71K | 0 | - |
| Total Liabilities | - | 13.03M | 5.26M | 4.35M | 4.90M |
| Current Liabilities | - | 12.50M | 2.10M | 4.34M | 4.59M |
| Long Term Debt | - | 500.00K | 3.06M | - | - |
| Total Debt | - | 6.85M | 3.28M | 3.35M | 3.44M |
| Total Equity | - | 15.71M | 24.85M | 21.13M | 23.16M |
| Shares Outstanding | - | 3.57M | 5.18M | 5.61M | 8.14M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -12.32M | -7.72M | -1.19M | -1.84M |
| Investing Cash Flow | - | 2.44M | 624.77K | 58.62K | 0 |
| Financing Cash Flow | - | 6.63M | 4.09M | 0 | 4.42M |
| Capital Expenditure | -137.78K | -186.92K | -3.02K | - | - |
| Free Cash Flow | - | -12.51M | -7.73M | -1.19M | -1.84M |
| Net Change in Cash | - | -3.25M | -3.01M | -1.13M | 2.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 6.2% | 2.4% | - | - |
| Operating Margin % | - | -1,325.2% | -2,457.5% | - | - |
| Net Margin % | - | -756.2% | -654.8% | - | - |
| ROE % | - | -62.4% | -11.4% | -20.2% | -5.9% |
| ROCE % | - | -205.3% | -57.2% | -25.5% | -12.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 0.20% | 5.85K | $27.60K |
| 2 | Citadel Advisors Llc | 0.08% | 2.45K | $11.56K |
| 3 | Citigroup Inc. | 0.02% | 640 | $3.02K |
| 4 | Osaic Holdings Inc. | 0.02% | 550 | $2.60K |
| 5 | SBI Securities Co., Ltd. | - | 1 | $4 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NIKI
A live presentation from Niki BioSolutions is set for Sept. 14 at 10:30 a.m. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOVzNrOG1ZOUgyVkJ2MHBUNmRwZ09BU0ItUGdYY01HNWpBbHBqaEFLNkswaGdXTFVuUXl4RXl5aFpYUTByZEdwYUFKek5NTFNmRjBFaFBwNGlCRDBxckJBNDljUG9hMURBUlkwMUtGQlRHQ0tSZjJWY3BaVC1PcjQ0MVE3OHVMRWVnMktTdF…
Niki BioSolutions (NASDAQ: NIKI) Names Ian Huen CEO and Alidad Mireskandari President with 20,000 RSUs Awarded - Kalkine Media
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxOTFR1SDUzTHQ5UExjbzVjM1pxS1RrYUlXRlVuUzNYNWlUWWRKa2NVZlExS2JFVEVOeXVpald0S29qdVRNZWdRYlZWTU1YVGtMbzdFTUJZOHdudkZvTWlmbVpfLVk2ZVNpV2N6dzNvQzAxVU1kX0NiUDVMMU14ak1qSS1YSllVTEF4RU5QZV…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE02ZENiR28tVTQ2RFN6cF9LcmZmckF0TGdMRzJHS1VKMzFHWUg3dEhxeFRBWkdUYkJ3NEhWMW1XXzQxR3BFUTNLLVpoOFN5SFV0?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdnlCNnFWV0E1bmhxbXBNZFRzNmtoS1oxeG1rSzVlQ0hmRmcwUjgxWHZSRVVEX3BrWk5rcDNUMy1Wa0d6Wk04c3V6MHpEOGNiOU1kS0lLakxWRmtQZzVpVmIxb2wxUEdEOS1GQUFwdktSbVF4bXF0NHNvN2ZEQTFxeGt2SzBCVVBDclVxSG…
Niki BioSolutions, Inc. (NASDAQ: NIKI) Share Price, NIKI Stock News, NIKI Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9VQWNMSTZhYkh6MnJBYzk5MGlIZEU4dFpacG5zZFBYd194bTh2SG80cFlIaWRCR29XNzBDakxPTTNUQmJwX3hIVXU0OEhFSEtrczN2ck5n?oc=5" target="_blank">Niki BioSolutions, Inc. (NASDAQ: NIKI) Share Price,…
Inventory turnover of Niki BioSolutions, Inc. – NASDAQ:NIKI - tradingview.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNTkxwWW04eXJlWXVIbE5xSWItcHFkNFdVRmJLMWIwX21EUDIwLVlmWjdfZ3lPNWNsbGJTWFNqS0thQjZxd0VuMDBLRmZzSVh3NFJqSzNxYjRvN21iYmVHdXM2a0ZDY0ZUM0lHTGpzQkxQTlU0RmZaZ0RNcHBoLVRaRG9pZnVPXzMxMHlYcU…
NIKI — Frequently Asked Questions
What is the current share price of Niki BioSolutions, Inc. (NIKI)?
As of 2026-09-19 21:16 PDT, Niki BioSolutions, Inc. (NIKI) trades at $6.28 on NasdaqCM. Its 52-week range is $6.20 to $42.50.
What is the market capitalisation of NIKI?
Niki BioSolutions, Inc. (NIKI) has a market capitalisation of $3.99M on NasdaqCM.
What is the P/E ratio of NIKI?
NIKI trades at a trailing price-to-earnings (P/E) ratio of -2.17. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.18.
What is the return on equity (ROE) of NIKI?
NIKI has a return on equity (ROE) of -17.05%. Its return on capital employed (ROCE) is -12.89%.
Is NIKI a good stock to buy?
This page provides a data-driven analysis of Niki BioSolutions, Inc. (NIKI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.